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A single gene defect causing claustrophobia
A El-Kordi1,2,8, A Ka¨stner1,8, S Grube1,8, M Klugmann3,9, M Begemann1,2, S Sperling1, K Hammerschmidt4, C Hammer1,
B Stepniak1, J Patzig3, P de Monasterio-Schrader3, N Strenzke5, G Flu¨gge2,6, HB Werner3, R Pawlak7, K-A Nave2,3
and H Ehrenreich1,2
Claustrophobia, the well-known fear of being trapped in narrow/closed spaces, is often considered a conditioned response to
traumatic experience. Surprisingly, we found that mutations affecting a single gene, encoding a stress-regulated neuronal
protein, can cause claustrophobia. Gpm6a-deficient mice develop normally and lack obvious behavioral abnormalities. However,
when mildly stressed by single-housing, these mice develop a striking claustrophobia-like phenotype, which is not inducible in
wild-type controls, even by severe stress. The human GPM6A gene is located on chromosome 4q32-q34, a region linked to panic
disorder. Sequence analysis of 115 claustrophobic and non-claustrophobic subjects identified nine variants in the noncoding
region of the gene that are more frequent in affected individuals (P¼ 0.028). One variant in the 30untranslated region was linked
to claustrophobia in two small pedigrees. This mutant mRNA is functional but cannot be silenced by neuronal miR124 derived
itself from a stress-regulated transcript. We suggest that loosing dynamic regulation of neuronal GPM6A expression poses a
genetic risk for claustrophobia.
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Introduction
The neuronal tetraspan membrane glycoprotein Gpm6a
has been implicated in neurite outgrowth and dendritic
spine formation,1–3 but the lack of a mouse mutant has
prevented any in vivo analysis of Gpm6a function. Specifi-
cally, the observation that Gpm6a expression in rodent brain
is downregulated by cortisol or following physical restraint
stress4 has been puzzling. As stress is a key factor for
triggering mental disorders,5 we investigated the behavioral
consequences of resident-intruder stress in mice lacking the
Gpm6a gene. We report here the unexpected finding
that the neuronal gene Gpm6a constitutes a genetic cause
of a highly unusual ‘claustrophobia-like’ phenotype in null
mutant mice, which otherwise develop completely normally. In
fact, only Gpm6a mouse mutants that have experienced a
mild ‘social stress’ exhibit this ‘claustrophobia-like’ behavior.
Moreover, we translate this finding to human individuals,
where we find rare sequence variants in the GPM6A
gene associated with claustrophobia. Mechanistic insight is
provided by the demonstration of a human variant-specific
loss of GPM6A regulability. We conclude that regulability
of the GPM6A gene under stress is required to
avoid claustrophobia, which emerges as an unusual stress
response.
Materials and methods
Generation and characterization of Gpm6a null mutant
mice. All experiments were approved by the local Animal
Care and Use Committee in accordance with the German
Animal Protection Law. Mice with a targeted inactivation of
the Gpm6a gene were generated. First a gene-targeting
vector (Figure 1a) was constructed. From the cloned mouse
(129SV) Gpm6a gene, a 6.5-kb fragment of intron 2 became
the long homologous arm. A 1.5-kb fragment that included
the 30-part of intron 1 and 6 bp at the 50-end of exon 2 became
the short homologous arm. It was cloned with tailored PCR
primers introducing Hind3 (50) and BamH1 (30) restriction
sites. For negative selection, a neomycin-resistance gene
(neo) under control of the herpes simplex virus (HSV)
thymidine kinase (tk) promoter (kindly provided by R
Sprengel, MPI Heidelberg) was utilized. The neomycin
cassette was subcloned with tailored PCR primers introdu-
cing at both the 50- and the 30-end BamH1 restriction sites
and translation termination codons in all reading frames. For
positive selection, a Cla1 fragment of the HSV-tk under
control of the HSV-tk promoter was subcloned into the
vector. The construct was verified by molecular sequencing,
and the vector backbone (pKSþ bluescript, Stratagene
Heidelberg, Germany) was linearized with Not1. Using
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standard procedures,6 R1 mouse embryonic stem cells
(R1-ES, provided by A Nagy, Toronto, Canada), suspended
in phosphate-buffered saline (PBS) with 40 mg linearized
targeting vector, were electroporated using a Bio-Rad
GenePulser (240 V and 500mF, Bio-Rad, Munich, Germany).
Transfected embryonic stem cells (2 107) were cultured on
gelatinized 10-cm dishes (Falcon, Heidelberg, Germany) for
1 day and then selected with 300mg ml 1 G418 and 2 mM
Gancyclovir. On day 10 after electroporation, 386 resistant
clones were picked and one with homologous recombination
was identified by semi-nested PCR. Amplification was (1) with
forward primer (50-GGGCTGACTTTTGGATTTTGTGG-30)
and reverse primer (50-GCCTCTCCACCCAAGCGGCCG
GAGAACCTGCGTGC-30) and (2) on the first PCR product
with alternative reverse primer (50-GCAATCCATCTTGTT
CATGGC-30). Embryonic stem cells were microinjected into
C57Bl6/6J blastocysts that were transferred to pseudo-
pregnant foster mothers. Highly chimeric males (N¼ 4) were
obtained that were bred to C57Bl6/6J females. We interbred
heterozygous offspring to obtain homozygous mutant mice,
which were born at the expected Mendelian frequency.
Gpm6a null mutant mice are viable and fertile. For genotyp-
ing (Figure 1b), genomic DNA was isolated from tail biopsies
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Figure 1 Generation of Gpm6a null mutant mice and discovery of behavioral consequences following stress. (a) Strategy to inactivate the mouse Gpm6a gene.
A neomycin resistance cassette flanked by translation stop codons in all reading frames was fused into exon 2, which is the first exon present in all Gpm6a transcripts. (b) PCR
genotyping to identify wild-type (WT) and mutant Gpm6a alleles. (c) Immunoblot analysis of cortex homogenates using antibodies directed against Gpm6a or tubulin, with or
without prior deglycosylation using PNGaseF. Gpm6a was undetectable in Gpm6a null mutants. Note that the abundance of Gpm6a was considerably reduced in
heterozygous mice. (d) Immunohistochemistry of brain sections with antibodies directed against Gpm6a or the related proteolipid protein (PLP). Note that Gpm6a was not
detected in Gpm6a null mutant mice that showed unchanged PLP expression. (e) Elevated plus maze (EPM) behavior of psychosocially stressed (resident-intruder paradigm)
as well as of sham-stressed Gpm6a null mutants (KO) reveals a prominent claustrophobia-like phenotype (N¼ 17–19 per group). (f) Sample track recording of EPM
performance, illustrating a Gpm6a mutant spending much less time in closed arms compared with its WT littermate. (g) Single housing (a prerequisite of performing the
resident-intruder stress) is sufficient to induce a claustrophobia-like phenotype in Gpm6a mutants (N¼ 7–9 per group), which is absent upon group housing, and (f) to reveal a
clear genotype difference in the expression of a stress-regulated gene, Fkbp5, in mouse amygdala (N¼ 7–9 per group). Mean±s.e.m. presented. DAPI, 40-6-diamidino-2-
phenylindole; HSK-tk, herpes simplex virus-thymidine kinase.
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to manufacturer’s directions. In a PCR co-amplification
reaction, the presence of the Gpm6a wild-type (WT) allele
was shown using forward primer #1 (50-TTGCTCTTCTAC
AGGGTGCT-30) and reverse primer #2 (50-CCTCCA
TCCTCTGTCATTCC-30), which yielded a 560-bp fragment.
We identified the targeted allele with forward primer #1 and
reverse primer #3 (50-GCAATCCATCTTGTTCAATGGC-30),
yielding a 310-bp fragment. For protein analysis (Figure 1c),
we prepared total cortex lysates from WT, heterozygous and
homozygous mice and determined the protein concentration
according to Bradford, and boiled the samples (5 min) before
loading. For immunoblot, we separated 40mg lysate by 12%
SDS-polyacrylamide gel electrophoresis and transferred the
samples on poly(vinylidene fluoride) membranes (Hybond-P,
Amersham Biosciences, Glattbrugg, Switzerland). We
blocked the membrane in 5% milk powder in PBS with
0.1% Tween (30 min at 37 1C). Antibodies were directed
against the C-terminus of Gpm6a (#24983; 1:500) or tubulin
(Sigma, Heidelberg, Germany; 1:5000) and applied in
blocking buffer (over night, 4 1C). Following wash, membrane
was incubated with horseradish peroxidase-conjugated sec-
ondary antibody (Dianova, Hamburg, Germany, 1:5000 in
blocking buffer). Immunoreactive bands were visualized by
enhanced chemiluminescence (Pierce, Bonn, Germany). For
immunohistochemistry (Figure 1d), WT and Gpm6a null
mutant mice were anesthetized with Avertin (250 mg/kg body
weight; Sigma), perfused with Hank’s balanced salt solution,
followed by 4% formaldehyde in PBS and the isolated brains
were post-fixed for 1 h. Vibratome sections (thickness 12mm,
Leica VT 1000S, Leica Biosystems, Wetzlar, Germany) were
permeabilized with 0.4% Triton X-100 in PBS (30 min, room
temperature), blocked in 4% horse serum in PBS (30 min,
room temperature) and incubated with antibodies against
Gpm6a (M6, rat monoclonal, 1:25; kind gift by Carl Lagenaur,7
Pittsburgh, USA) or proteolipid protein (A431, rabbit
polyclonal, 1:500)8 at 4 1C for 24 h. After wash, sections were
incubated with appropriate fluochrome-coupled secondary
antibodies (Dianova, Hamburg, Germany; 2 h, room tempera-
ture) and washed three times. Sections were imaged with
Leica DMRXA and OpenLab 2.0 software (Improvision,
Tu¨bingen, Germany).
Behavioral testing. For behavioral testing, mice were
housed in groups of three to five in standard plastic cages,
food and water ad libitum. The temperature in the colony
room was maintained at 20–22 1C, with a 12-h light/dark
cycle (light on at 0700 hours). Behavioral experiments were
conducted by an investigator, blinded to the genotype, during
the light phase of the day (between 0800 hours and 1700
hours). For behavioral experiments, eight different cohorts of
mice were used. The order of testing in the first cohort was as
follows: elevated plus maze (EPM), open field, hole board,
rotarod, pre-pulse inhibition, fear-conditioning, visual cliff. In
further cohorts, EPM release in closed arms, EPM in the
dark, mouse light/dark box test, mouse wide/narrow box test,
EPM retesting (‘exposure treatment’) and hearing were
performed. For electroretinogram, olfaction testing and
corticosterone determination upon metabolic cage exposure,
separate cohorts were used. Age of mice at the beginning of
testing was 19 weeks. Inter-test interval varied depending on
the degree of ‘test invasiveness’ but was at least 1 day. During
all tests, the investigator was ‘blinded’, that is, unaware of
mouse genotypes. For comprehensive test description of
basic tests, that is, EPM, open field, hole board, rotarod, visual
cliff test (vision), buried food finding test (olfaction), sucrose
preference test (motivation), pre-pulse inhibition, cued and
contextual fear-conditioning, and ultrasound vocalization
analysis, please see El-Kordi et al.9 Described in the following
are additional, modified or specifically designed tests.
EPM with release in closed arms. In this modified version,
mice were placed in the closed arms in the same plus-maze
described above. This test was done to address potential
motor factors influencing the time spent in arms. The test
was otherwise conducted in the same manner as the
classical EPM.
EPM in darkness. This test was again performed like the
classical EPM, just in full darkness to address potential
visual/perceptual factors affecting behavior in open/closed
space. The behavior of mice was monitored via infrared
camera.
Hot plate test. The hot plate test is used as a measure of
pain sensitivity. Mice were placed on a metal plate (Ugo
Basile, Comerio, Italy), preheated up to 55 1C. The latency of
hind paw licking or jumping was recorded. Mice were
removed from the platform immediately after showing the
response. A 40-s cutoff time was supposed to prevent
wounds, although none of the tested mice reached it.
Assessment of hearing by the acoustic startle response.
Individual mice were placed in small metal cages (90
40 40 mm3) to restrict major movements and exploratory
behavior. The cages were equipped with a movable platform
floor attached to a sensor that records vertical movements of
the floor. The cages were placed in four sound-attenuating
isolation cabinets (TSE GmbH, Bad Homburg, Germany).
Startle reflexes were evoked by acoustic stimuli delivered
from a loudspeaker that was suspended above the cage and
connected to an acoustic generator. The startle reaction to
an acoustic stimulus (pulse), which evokes a movement of
the platform and a transient force resulting from this
movement of the platform, was recorded with a computer
during a recording window of 100 ms and stored for further
evaluation. The recording window was defined from the
onset of the acoustic stimulus. An experimental session
consisted of a 2-min habituation to 65 dB background white
noise (continuous throughout the session), followed by a
baseline recording for 1 min at background noise. After
baseline recording, stimuli of different intensity and fixed
40 ms duration were presented. Stimulus intensity was varied
between 65 and 120 dB, such that 19 intensities from this
range were used with 3 dB step. Stimuli of the each intensity
were presented 10 times in a pseudorandom order with an
interval ranging from 8 to 22 s. The amplitude of the startle
response (expressed in arbitrary units) was defined as the
difference between the maximum force detected during a
recording window and the force measured immediately
before the stimulus onset. Amplitudes of responses for each
Claustrophobia in Gpm6a null mutant mice
A El-Kordi et al
3
Translational Psychiatry
stimulus intensity were averaged for individual animals.
Mean values for each experimental group were plotted on
the graph to provide the stimulus–response curves.
Mouse light/dark box test. The apparatus (36 20.5 19
cm3) consisted of two equal acrylic compartments, one
roofed, dark and one white, with a 300 lx light intensity in the
white compartment and separated by a divider with an
opening (size: 5.7 5 cm2) connecting both compartments.
Each mouse was tested by placing it in the black/dark area,
facing the white one, and was allowed to explore the novel
environment for 5 min. The roof of the dark compartment was
closed after releasing the mouse. The number of transfers
from one compartment to the other and the time spent in the
illuminated side were measured. This test exploited the
natural conflict between the animal’s drive to explore a new
environment and its tendency to rather stay in a closed, dark
and protected environment and to avoid bright light.
Mouse wide/narrow box test. This inhouse-made box (test
arena: length 60 cm, width 60 cm and height 30 cm)
consisted of two equal (each 30 cm length) gray plastic
compartments. One compartment was wide and open, the
other one narrow (consisting of 30 5 30 cm3 corridor).
Mice were placed in the wide compartment, facing the narrow
corridor. Light intensity in the wide compartment was 300 lx,
in the corridor 150 l . Time to enter the corridor was
recorded by a stopwatch. The behavior was recorded
throughout the 10 min testing period by a PC-linked overhead
video camera. ‘Viewer 2’ software was used to calculate
velocity, distance travelled, number of visits of and time spent
in both compartments.
Electroretinogram. Before the experiments, animals were
dark adapted for at least 12 h and all preparations were
carried out under dim red light.10 Mice were anaesthetized by
intraperitoneal injection of ketamine (0.125 mg g 1) and
xylazine (2.5 mg g 1). Supplemental doses of 1/4 the initial
dose were administered when changes in the constantly
monitored electrocardiogram or movements indicated that
the animals were waking up. Mice were placed on a heated
mat (Hugo Sachs Elektronik–Harvard Apparatus, March,
Germany) that kept the body temperature constant at 37 1C
under the control of a rectal thermometer. The head of the
mouse was placed inside a custom-designed Ganzfeld bowl
illuminated by a ring of 20 white light-emitting diode. The
pupil of the left eye was dilated with 1% atropine sulfate and a
silver wire ring electrode was coupled to the corneal surface
using electrode gel. The eye and electrode were kept moist
by a drop of 0.9% saline applied every 30 min. Subcutaneous
needle electrodes were inserted between the eyes (refer-
ence) and near the tail (ground). Electrical potentials were
amplified 1000 times, filtered between 0.1 and 8 kHz and
notch-filtered at 50 Hz using custom-designed hardware. The
Tucker Davis System III hardware and BioSig software
(Tucker-Davis Technology, Alachua, FL, USA) were used for
Elevated Plus Maze Exposure 'Therapy'
EPM
























































































































































Figure 2 Male Gpm6a mutants show a strong claustrophobia-like phenotype on top of mild anxiety features. (a) Behavior of Gpm6a knockout (KO) and wild-type (WT)
littermates in classical elevated plus maze (EPM); (b) in EPM performed in the darkness; and (c) in EPM upon release in closed arms. (d) Weekly exposure to EPM (over 3
weeks) led to reduction of closed arm aversion in Gpm6a KO. This adjustment also explains the weaker closed-arm avoidance seen in mice of b and c, which had had one
previous exposure to EPM. (e) In a newly developed wide/narrow box test, WT mice spent more time in the narrow area (left graph), whereas Gpm6a KO did not show narrow
space preference. (f) In the light/dark box, Gpm6a KO mice entered the light area faster; (g) explored less holes (requiring nose pokes in narrow holes); (h) spent less time in
the center of the open field, and (i) exerted higher baseline freezing in the fear-conditioning chamber. (j) Exposed to narrow metabolic cages for 3 h, Gpm6a KO excreted
higher levels of corticosterone via urine. (a–c): N¼ 17–18; (d): N¼ 8; (e): N¼ 32–35; (g–h): N¼ 17–18; (i, j): N¼ 12. Mean±s.e.m. presented.
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stimulus control and recordings. Scotopic responses to 10
white light flashes were averaged for each stimulus condi-
tion. Interstimulus intervals were 5 s for light intensities below
1 cds m 2 and 17 s for light intensities above 1 cds m 2. The
amplitude growth functions and latencies of the A-waves,
B-waves and oscillatory potentials in response to 0.1, 1 and
5 ms long-light flashes ranging between 0.0003 and
10 cds m 2 was analyzed using custom-written matlab
(Mathworks, Natick, MA, USA) software.
Corticosterone excretion. Urine samples were collected
using inhouse-made metabolic cages. Mice were placed in
small, narrow metal cages (90 40 40 mm3) to restrict
major movements and exploratory behavior, thus resulting in
stress-induced corticosterone release. These cages had a
wire-mesh floor enabling urine collection via a funnel. The
funnel was fixated on top of a collecting flask. Mice (12 per
genotype) were placed in the metabolic cages at 2200 hours
for 3 h each. Urine was collected at 0100 hours. Concentra-
tions of corticosterone were measured using a commercially
available EIA kit (BIOTREND, Cologne, Germany) according
to the manufacturer’s protocol. Urine creatinine was
determined photometrically (Jaffe method). Sample analysis
of WT and knockout (KO) animals was performed blinded
and in random order. Values were expressed as nmol per
day per g body weight.11
Resident-intruder (psychosocial stress) test. The procedure
is described in detail elsewhere.12,13 Briefly, male mice of
both genotypes (28 days old) were randomly assigned to
either the ‘stress’ or ‘sham stress’ group. As intruders, they
were subjected for 21 days (1 h daily, from 0900–1000 hours)
to resident male mice (male FVB, 2–3 months old, habituated
to resident cages for X10 days). To prevent injuries, direct
interaction was immediately terminated at the first attack
(usually occurring after a few seconds) by putting a grid cage
(140 75 60 mm3) over the intruder. Afterwards, intruder
mice were placed back in their home cage. Mice were
confronted with a different resident every day. Sham stress
consisted of placing the intruder mouse in an empty novel
cage for 1 h.
Restraint stress paradigm. Mice were kept undisturbed for at
least 1 week until a single 6-h restraint stress was performed
in a separate room (with mice left in their home cages and put
in wire mesh restrainers, secured at the head and tail ends
with clips) during the light period of the circadian cycle as
described.14 Control animals were left undisturbed.
Amygdala dissection. Mice were anaesthetized (intraperito-
neal sodium pentobarbital 50 mg kg 1) and perfused trans-
cardially (ice-cold PBS). Amygdalae were dissected from a
coronal slice  0.58 to  2.3 mm relative to Bregma and
stored in RNA later (Qiagen) at 4 1C until processed.14
Quantitative reverse transcription-PCR from amygdala.
Amygdala tissue was homogenized in Quiazol (Qiagen,
Hilden, Germany). Total RNA was isolated by using the
miRNeasy Mini Kit (Qiagen). First strand cDNA was
generated from total RNA using N9 random and Oligo(dT)
18 primers. The relative concentrations of mRNAs of interest
in different cDNA samples were measured out of three repli-
cates using the threshold cycle method (deltaCt) for each
dilution and were normalized to the normalization factor of
Hprt1 and H2afz genes calculated by the geNorm analysis
software. Reactions were performed using SYBR green PCR
master mix (ABgene, Foster City, CA, USA) according to the
protocol of the manufacturer. Cycling was done for 2 min at
50 1C, followed by denaturation at 95 1C for 10 min. The
amplification was carried out by 45 cycles of 95 1C for 15 s
and 60 1C for 60 s. The specificity of each primer pair was
controlled with a melting curve analysis. For quantitative











miR124. First strand cDNA synthesis and reactions were
generated from total RNA using the TaqMan MicroRNA RT
Kit, TaqMan MicroRNA Assay for hsa-miR124, TaqMan
MicroRNA Assay for sno-RNA142 as a housekeeper and
TaqMan 2 Universal PCR Master Mix (ABgene) according
to the manufacturer’s protocol. Cycling was done with 10 min
denaturation at 95 1C and amplification for 40 cycles at 95 1C
for 15 s and 60 1C for 60 s.
Human sample
Claustrophobic subjects. The present study was approved
by the Ethics Committee of the Georg-August-University. A
total of 47 subjects with clinical diagnosis of claustrophobia
according to Diagnostic and Statistical Manual of Mental
Disorders IV (DSM-IV)15 were included (Table 1). Healthy
subjects (N¼ 13) were recruited by e-mail announcements in
the Max Planck Institutes of Experimental Medicine (MPIEM)
and Biophysical Chemistry (MPBPC). Patients suffering from
psychiatric conditions other than psychotic disorders (N¼ 16;
that is, N¼ 7 affective disorder, N¼ 5 anxiety disorder, N¼ 2
substance use disorder, N¼ 2 others) were recruited from
the psychiatric hospital of the Georg-August-University
Go¨ttingen. In addition, N¼ 18 schizophrenic individuals with
a claustrophobic phenotype were selected from the GRAS
data collection.16 Claustrophobic subjects were invited to the
outpatient unit of the MPIEM for examination. In the case of
GRAS patients, extensive telephone interviews were per-
formed instead. Subjects underwent detailed claustrophobia
relevant phenotyping, after validation of diagnoses using
DSM-IV criteria15 by a trained psychologist/psychiatrist. The
subsequent examination procedure comprised a short ques-
tionnaire regarding sociodemographic information, history of
physical and psychiatric diseases, specifically for this project
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developed abbreviated German version of the Claustropho-
bia Questionnaire (CLQ)17 (Short CLQ-G) and the screening
questions of the Structured Clinical Interview of Diseases18
for anxiety disorders.
Non-claustrophobic subjects. A total of 68 subjects, who did
not suffer from claustrophobia, were matched to the
claustrophobic subjects regarding age, gender and clinical
diagnosis where applicable (Table 1). Again, healthy subjects
(N¼ 14) were recruited by e-mail announcements in the
MPIEM and MPBPC. Patients suffering from psychiatric
conditions other than psychotic disorders (N¼ 29; that is,
N¼ 18 affective disorder, N¼ 4 general anxiety disorder,
N¼ 4 substance use disorder, N¼ 3 others) were recruited
Table 1. Comparison of sociodemographic, general clinical and anxiety/claustrophobia relevant parameters in claustrophobic and non-claustrophobic subjects









Mean±s.d. Mean± s.d. Mean± s.d.
Sociodemographics
Age in years 43.56±13.22 43.87±12.11 43.35±14.02 0.733
Education in years 14.43±3.55 14.31±3.85 14.52±3.35 0.830
N % N % N % Effect P b
Gender
Female 81 70.4 13 27.7 21 30.9 0.139 0.710
Male 34 29.6 34 72.3 47 69.1
Ethnicity
Caucasian 112 97.4 47 100.0 65 95.6 2.129 0.546
African 1 0.87 — — 1 1.47
Other 2 1.73 — — 2 9.94
Marital status
Single 57 49.6 24 51.1 33 48.5 3.545 0.471
Married 33 28.7 12 25.5 21 30.9
Divorced 19 16.5 11 23.4 11 16.2
Widowed 3 2.6 — — 3 4.4
Main diagnoses according to DSM-IV
No clinical diagnosis 27 23.5 13 27.7 14 20.6 1.135 0.567
Schizophrenia 43 37.4 18 38.3 25 36.8
Other clinical diagnoses 45 39.0 16 34.0 29 43
Prevalence of anxiety disorders
Comorbid anxiety disorderc 68 59.1 29 61.7 39 57.4 0.702
Panic disorder 29 25.2 15 31.9 14 20.6 0.194
Agoraphobiad 56 48.7 47 100.0 9 13.2 o0.0001
Ssocial phobia 18 15.7 9 19.1 9 13.2 0.440
Specific phobia 38 33.0 20 42.6 18 26.5 0.106
Generalized anxiety disorder 13 11.3 7 14.9 6 8.8 0.375
Obsessive compulsive disorder 18 15.7 9 19.1 9 13.2 0.440
Mean±s.d. Mean±s.d. Mean±s.d. P a
Claustrophobia Relevant Items (Short CLQ-G)
Subscale ‘restriction’
Dark room 2.18±1.66 3.25±1.22 1.44±1.51 o0.000001
Well-lit room 1.51±1.46 2.53±1.27 0.78±1.12 o0.000001
Sleeping bag 1.04±1.45 1.87±1.58 0.47±1.01 o0.000001
Trunk 2.18±1.67 3.53±1.04 1.25±1.36 o0.000001
MRI scanner 1.65±1.67 3.17±1.05 0.60± 1.11 o0.000001
Mean of subscale 1.71±1.36 2.87±0.87 0.91±1.00 o0.000001
Subscale ‘suffocation’
Elevator 1.07±1.39 2.13±1.36 0.34±0.84 o0.000001
Breathe 0.83±1.09 1.26±1.24 0.54±0.87 o0.001
Crowded room 1.82±1.57 3.04±1.12 0.97±1.25 o0.000001
Under a car 1.23±1.44 2.17±1.51 0.59±0.97 o0.000001
Sauna 1.00±1.44 2.04±1.56 0.28±0.75 o0.000001
Mean of subscale 1.19±1.08 2.13±0.83 0.54±0.70 o0.000001
Mean of questionnaire 1.45±1.17 2.50±0.74 0.73±0.82 o0.000001
Abbreviation: MRI, magnetic resonance imaging.
aMann–Whitney U-test.
bFisher’s exact test/w2-square test.
cAnxiety disorders other than agoraphobia.
dAgoraphobia includes claustrophobia.
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from the psychiatric clinic of the Georg-August-University
Go¨ttingen. Furthermore, 25 schizophrenic non-claustropho-
bic individuals were selected from the GRAS data collec-
tion.16 The examination procedure comprised the same
battery of questionnaires as for the claustrophobic subjects
(above).
Pedigrees. To explore whether particular variations in
GPM6A are transmitted in families together with claustro-
phobia, we tried to contact all available family members of
the three claustrophobic individuals carrying the genetic
variation at locus c.*1834T4C. Only for two of the subjects,
SIWO and THKA (Figure 3b), it was possible to contact a
sufficient number of relatives. Claustrophobia diagnosis
according to DSM-IV criteria was confirmed by a telephone
interview carried out by a trained psychologist. Swabs for
genetic analysis and a short sociodemographic question-
naire, also containing items regarding the history of physical
and psychiatric diseases, the Short CLQ-G and the screen-
ing questions of the Structured Clinical Interview of Diseases
for anxiety disorders,18 were communicated via mail.
Abbreviated German version of the CLQ (Short CLQ-G).
To quantitatively assess the severity of claustrophobic
anxiety, nine items of the CLQ17,19 were selected and
translated into German language (Supplementary Table 1).
One item measuring fear experienced during magnetic
resonance imaging was added to the restriction subscale
because this situation may induce claustrophobia.20,21 The
CLQ is the most commonly used questionnaire for the
psychological assessment of claustrophobia and has excel-
lent psychometric properties (Cronbach’s a: 0.95; test–retest
reliability: 0.89).17 It is composed of two subscales measur-
ing two distinct but related fears: fear of restriction and fear of
suffocation. Anxiety severity is measured on a 5-point Likert
scale. To cover both subscales, five items from the
suffocation and four items from the restriction subscale with
high ecological validity were selected for construction of the
Short CLQ-G. Given the substantial reduction in item number
(B60%), the Short CLQ-G still achieves high internal
consistency (total scale: 0.932, restriction: 0.909, suffocation:
0.835) and split-half reliability (0.952, splits matched for
mean item difficulty) for the whole subject sample (N¼ 115;
N¼ 47 claustrophobic subjects; N¼ 68 non-claustrophobic
subjects; Supplementary Table 1).
GPM6A sequencing. DNA from all subjects participating
in this study (N¼ 115) was isolated from blood with the
Figure 3 Genetic analysis of GPM6A. (a) Sequencing strategy and overview of the detected variants. Displayed are the coding exons (filled boxes) and the noncoding
region of GPM6A (empty box). Arrows indicate rare variants found. Frequencies of rare variants in cases (black) versus controls (gray) are given. (b) Pedigrees of two
claustrophobic individuals (SIWO and THKA), carrying the mutation at locus c.*1834 (position 2882 in human GPM6A transcript variant 1, mRNA; NM_005277.3), suggesting
an association between this mutation and the claustrophobic phenotype. (c) Highly phylogenetically conserved genomic structure surrounding c.*1834T4C within the seed
sequence of miR124 in the 30untranslated region of GPM6A. (d) Expression analysis after miR124 nucleofection. Shown are the results of GPM6A RNA expression in
peripheral blood mononuclear cells (PBMCs) after nucleofection with miR124 from two patients and six controls (that is, not carrying the variant; age, gender and disease
matched; three controls per patient). Results were standardized to the results after just a pulse. (e) Restraint stress induces upregulation of miR124 in the amygdala of male
mice, identifying this miR as a stress-regulated transcript (N¼ 22 per group).
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JET Quick Kit (Genomed, Loehe, Germany). For analysis of
pedigree members (swabs), DNA was isolated with the
Isohelix DNA Swab Kit (Biolab Products, Goedenstorf,
Germany). PCR reaction: All exons, the putative promoter
region of Ex2B and the 30 untranslated region (30UTR) of
GPM6A were PCR-amplified from respective samples.
Primers are listed below. Sequencing: The PCR amplicons
were purified from unincorporated primers and deoxyribonu-
cleotide triphosphates by digesting with 1 U Shrimp Alkaline
Phosphatase und 5 U Exonuclease I (Exo) according to the
manufacturer’s instructions (USB Europe GmbH, Staufen,
Germany). Sequencing was carried out using the dideoxy
chain termination method with the BigDye Terminator v3.1
Cycle Sequencing Kit on a 3730XL DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). Raw data were
processed with Sequencing Analysis 5.2 (Applied Biosys-
tems) and with different modules of the software package
Lasergene 7.0 (DNASTAR, Madison, WI, USA).
Primers for GPM6A sequencing approach
Amplified region Primer sequence (50-30) Size
(bp)






Exon 2b fw GAGGAGAGAAAAGGAAAACACAG 755
rv GAAACATTCATTAGCCTTACTGG
Exon 3 fw GAAAGTCTGGGTTGGGAAGGA 788
rv GATTTGTACCTGGCACTATTCTA
Exon 4 fw GAACCAGGGAAGAGGAGAAG 694
rv CCATACATCAATCAACAGTG
Exon 5 fw GCCAAGATATGATTTTCCAGCAG 709
rv GGGAGGATAAAAGTAGAATGC
Exon 6_7 fw GGAACTTGCTTAGATTTGATTAG 955
rv GACTTACTTACCCATTGTTTTCC
Exon 8* fw CGAGATAGCAAGGTGTAATGAAG 904
rv CATAAACATGAGTAATCTGAGG
30UTR* fw GAAGATCAGTGGCCATATTAC 1543
rv ATTGTACTTGAAAAGAATTCACAC
*For sequencing exon 8 and the associated 30UTR additional




Computational micro RNA (miRNA) search. To explore
putative miRNA-binding sites in the GPM6A 30UTR, several
analyses were performed. TargetScan, version 6.2 (http://
www.targetscan.org/) was used to identify miRNA-binding
sites. Screening and DDG prediction analysis for both alleles
of GPM6A were carried out using established algorithms
(http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html).
Expression analysis after nucleofection. Peripheral blood
mononuclear cells (PBMCs) of claustrophobic patients with
the mutation in the 30UTR (N¼ 2) and three matches per
subject were freshly isolated using the standard Ficoll-Paque
Plus isolation procedure (GE Healthcare, Munich, Germany).
Using the Amaxa Nucleofector II Device (T-020), 6 106
cells were transfected with neg miRNA #2 or hsa-miR124
(Applied Biosystems) and cultured in RPMI supplemented
with 10% fetal calf serum. After 24 h, cells were harvested
and RNA extracted with the miRNeasy Mini Kit (Qiagen).
cDNA was synthesized using 200 U SuperScriptIII (Invitro-
gen, Karlsruhe, Germany). For quantification with quantita-
tive reverse transcription-PCR, the cDNA was used 1:10
diluted and four replicates per sample were performed; to 4ml
diluted cDNA, 5 ml Power SYBR mix (Applied Biosystems)
and 1 pmol of each primer (see below) were added.
Cycle threshold (CT) values for GPM6A were standardized





Statistical analyses. Data were analyzed using SPSS for
Windows version 17.0 (SPSS Inc., Chicago, IL, USA; http://
www.spss.com) (human data analyses) and Prism 4 for
Windows version 4.03 (GraphPad Software, Inc., La Jolla,
CA, USA) (mouse data analyses). Unless otherwise stated,
the data given in figures and text are expressed as
mean±s.e.m., and were compared by two- or three-way
analysis of variance with post-hoc planned comparisons or
by analysis of variance for repeated measurements,
Mann–Whitney U-test and w2 test, where appropriate.
Results
Gpm6a null mutant mice appear essentially normal in
development and basic behavior. We have generated
Gpm6a null mutant mice (KO) to explore the role of Gpm6a in
the behavioral response to stress (Figures 1a–d). Homo-
zygous KO mice were born at the expected Mendelian
frequency and are long-lived. By western blot analysis,
heterozygous mice expressed about 50% of the protein
(Figure 1c), demonstrating that Gpm6a abundance can be
regulated at the transcriptional level in vivo (see below).
Gpm6a KO mice reproduce well and exhibit no obvious
developmental defects (data not shown). Also, in a basic
behavioral test battery, which included the analysis of motor
and sensory functions, motivation and sensorimotor gating,
we found no difference from WT littermate controls
(Supplementary Figure 1).
Mild stress induces a claustrophobia-like phenotype in
Gpm6a null mutant mice. Unexpectedly, when applying
the resident-intruder paradigm13 in order to assess the
response to experimental stress, we noticed that sham-
stressed Gpm6a null mutant mice exhibit a prominent
phenotype in the EPM, consisting of a specific avoidance
of closed arms. To our knowledge, such a behavioral
response, which we like to term ‘claustrophobia’ in mice,
has not been reported before. This phenotype is specifically
striking, because normal rodents rapidly seek closed and
narrow spaces to hide, which is a protective trait. Interest-
ingly, the claustrophobia-like phenotype was only marginally
amplified in those mutant mice that had experienced the
resident-intruder stress (Figures 1e,f). As a prerequisite for
applying this stress paradigm is prior single housing (of all
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mice), we asked whether the relatively mild stress of social
withdrawal might have been sufficient to trigger the claus-
trophobia-like phenotype in Gpm6a mutants. Indeed, single-
housed, but not group-housed, Gpm6a mutants showed
claustrophobia (Figure 1g). In these experiments, 10 days of
single housing were sufficient to cause downregulation of the
stress-responsive gene Fkbp522,23 in the amygdala of WT
mice. Importantly, this downregulation was absent in Gpm6a
mutant mice, demonstrating a perturbation of the normal
stress response even at the molecular level (Figure 1h). A
comparable result was obtained for Npy5r as another marker
of stress (data not shown).24
Extra behavioral tests underline the claustrophobia-like
phenotype in Gpm6a / mice. As claustrophobia-like
behavior in mice has to our knowledge never been reported
before, we performed a large number of extra behavioral
tests in eight independent cohorts of male mice in order to
substantiate this unusual phenotype. In fact, claustrophobia
upon single housing was found in all cohorts of Gpm6a
mutants and maintained when EPM was performed in
darkness, using infrared cameras or when mice were
released in closed arms (Figures 2a–c). This behavioral
response did not rely on whisker functions or vocalizations,
as confirmed by whisker cutting and ultrasound recording,
respectively (data not shown). Similar to an ‘exposure
therapy’ in humans, repeated EPM testings of mutants
reduced and ultimately eliminated the claustrophobia-like
behavior (Figure 2d; note also the weaker closed arm
avoidance of mutants in Figures 1g and 2b,c;
Supplementary Figure 2B, showing cohorts that already
had one previous EPM test session). Also, other tests
confirmed our diagnosis of ‘claustrophobia’, such as a
specifically designed wide/narrow box, a light/dark box and
the hole board test, in all of which mutant mice lacked
preference for narrow and dark spaces (Figures 2e–g), that
is, displayed a highly abnormal behavior, considering
that rodents naturally prefer these spaces to hide and
thereby protect themselves from predators.
Further tests demonstrated slightly increased general
anxiety, again reminiscent of the known human claustropho-
bic phenotype. Mutants spent less time in the center of
the open field and showed increased ‘baseline freezing’ in the
fear-conditioning box (Figures 2h,i). The collection of urine
from mutant mice that were kept for 3 h in narrow metabolic
cages, revealed a significantly higher corticosterone excretion
compared with their WT littermates (at similar urine creatinine
values: WT 0.35±0.08 versus KO 0.39±0.06 mg per g body
weight and day; N¼ 12/group; P40.1), indicative of an
increased stress level (Figure 2j). As phobias/panic disorders
in humans are more prevalent in females than in males,25 we
additionally examined female mutant mice and confirmed a
very similar behavioral pattern as in male mice, that is, an
unaltered basic behavior and the avoidance of closed arms in
EPM (Supplementary Figure 2).
First considerations on a functional compensation for
loss of Gpm6a in null mutant mice. Interpreting stress at
the level of gene expression changes is difficult, because the
encoded proteins can be ‘upstream’ or ‘downstream’ of
stress perception, and either contribute to or protect from
abnormal stress response. This complicates the prediction of
cause and effect in a pathological situation. Gpm6a
mRNA is downregulated by chronic social stress and also
following prolonged cortisol treatment.26 As stimulation of
the hypothalamus–pituitary–adrenal (stress) axis leads to
cortisol release, it is likely that downregulated Gpm6a
expression mediates adaptation of the brain to stress and
is therefore a healthy response that serves a feedback
function in neuronal circuits exposed to stressful signals. The
loss of Gpm6a in null mutant mice is clearly tolerated,
presumably by the functional compensation of structurally
related membrane proteins that are co-expressed in devel-
opment (but are likely not stress regulated). One candidate
for functional compensation is the neuronal Gpm6b gene,
which encodes a highly related protein27 with a similar (but
not identical) spatio-temporal expression in brain28,29 and
which is, unlike Gpm6a, not among the identified stress-
regulated genes.26,30 In fact, this gene is upregulated under
basal conditions in the amygdalae of Gpm6a mutant mice
(KO: 1.04±0.06; WT: 0.86±0.05, normed to Hprt1 and
H2afz; Po0.05). To further investigate compensatory func-
tions between the two genes, we cross-bred Gpm6a mutant
mice with a newly generated line of Gpm6b null mutant
mice.31 The resulting double-mutant mice develop normally
and reproduce well, but show 20% unexplained mortality at
age 1 month. Further evidence that Gpm6a and Gpm6b have
overlapping functions was found in cultured cortical neurons,
in which the loss of both proteins reduced the collapse
response of growth cones to soluble ephrin-B5, a repulsive
signal.31 This significant but clearly limited evidence of
compensation strongly suggests that several (but not all)
Gpm6a functions are redundantly served by Gpm6b and
presumably other neuronal proteins. If stress-induced down-
regulation of Gpm6a expression in vivo were part of a
neuroprotective stress response, it would be plausible that
Gpm6a null mutant mice can develop normally but are
selectively affected at the behavioral level, simply because
Gpm6a compensating genes (such as Gpm6b) lack the
necessary downregulation following stress exposure.
Selected genomic sequencing of GPM6A reveals
associations with claustrophobia. As polymorphisms of
human GPM6A, specifically in the noncoding region, could
likewise interfere with dynamic gene regulation, we explored
the association of this gene with a predisposition to human
claustrophobia. A sample of 115 adult subjects (N¼ 47 self-
reported claustrophobics and N¼ 68 non-claustrophobic
controls) were recruited and interviewed with special
emphasis on general anxiety and claustrophobia (Table 1).
The sociodemographic description of the human sample
revealed similar distributions between claustrophobic and
non-claustrophobic individuals with regard to age, educa-
tional background, gender, ethnicity and marital status.
Moreover, cases and controls were well matched for co-
morbid disease state. The prevalence of DSM-IV anxiety
disorders other than claustrophobia (Table 1, included under
agoraphobia) did not substantially diverge between claus-
trophobic cases and controls. More than half of the total
sample (59%) reported to suffer from at least one (additional)
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anxiety disorder. Expectedly, most individuals suffered from
any kind of specific phobia (33%), followed by panic disorder
(25%), social phobia and obsessive-compulsive disorder
(both 16%). Generalized anxiety disorder was least frequent
in our sample (11%). Claustrophobic subjects displayed higher
severity ratings on all 10 items of an abbreviated German
version of the CLQ17 (Short CLQ-G; essentially all Po000001).
Despite a 60% reduction in item number, the Short CLQ-G
showed still very good psychometric properties comparable
to the original instrument (Supplementary Table 1).
On all 115 subjects, we performed genomic sequencing of
GPM6A covering all exons and flanking noncoding regions.
This identified nine single-base substitutions in GPM6A, all of
which were rare (most of them previously unreported) variants
in the noncoding regions. Interestingly, in claustrophobic
individuals, the sequenced regions were significantly more
polymorphic than in non-claustrophobic controls (P¼ 0.028;
Figure 3a). To investigate whether particular variants of
GPM6A are also genetically linked to claustrophobia, we
examined two families that shared sequence abnormalities in
the 30UTR. This allowed us to include information on more
than one family member (N¼ 10) within two small pedigrees
(Supplementary Table 2). Indeed, the sequence variants in
the 30UTR/noncoding region exon8 were consistently found in
claustrophobic (but not in non-claustrophobic) individuals
(Figure 3b). Unfortunately, the pedigrees were too small to
assess significance. Interestingly, however, when comparing
all mutation carriers in our sample of 115 individuals with all
non-mutation carriers (independent of the claustrophobia
diagnosis) significantly higher scores for most claustrophobia-
relevant items were found associated with the mutation
status (Supplementary Table 3).
A single-base substitution in the 30UTR of GPM6A
delivers first mechanistic insight. To gain mechanistic
insight into the possible role of GPM6A sequence variants in
the noncoding region, we focused on the newly identified
substitution T to C at position c.*1834 in the 30UTR of
exon8, consistently associated with claustrophobia in the two
pedigrees. In vertebrates, the c.*1834-T allele is conserved
from human to zebrafish (Figure 3c). Mechanistically, this
position is of particular interest because it is located within
the seed sequence of miR124. This miRNA is expressed in
brain and highly conserved.32 Indeed, in silico analysis of the
T-to-C substitution predicts the complete loss of miR124
binding (DDG¼  8.11 kJ mol 1).
To assess the effect of miR124 on expression of the
endogenous human GPM6A gene, we obtained PBMCs, in
which the GPM6A transcript can be detected and quantified
by reverse transcription-PCR. When miR124 was over-
expressed by nucleofection of freshly isolated PBMCs,
steady-state levels of GPM6A mRNA were significantly
decreased in cells that were homozygous for the c.*1834-T
(WT) allele, but not in PBMCs from the heterozygous carriers
of the mutant c.*1834-C allele (Figure 3d). miR124 is
expressed in the adult brain, but has only been studied in
neuronal development32,33 and for its role in neuroplasti-
city.34,35 We asked whether miR124 is also found in the
amygdalae of mice and stress regulated. To this end, WT
mice were exposed to restraint stress for 6 h, followed
immediately by amygdala dissection. Indeed, we detected a
significant upregulation of miR124 (Figure 3e) under stress.
Discussion
The behavioral analysis of Gpm6a mutant mice has led to the
unexpected finding that a single neuronal gene can cause an
isolated behavioral defect, best described as claustrophobia.
Belonging to the category of agoraphobia/panic disorder,
claustrophobia is often assumed to be a conditioned
response, following a related traumatic experience.25,36 In
our model, claustrophobia-like behavior was observed in mice
with a strong genetic predisposition (that is, Gpm6a defi-
ciency) when combined with rather mild chronic stress.
Interestingly, there was no obvious relationship between the
quality of stress (that is, single-housing) and the very specific
avoidance behavior. This not only suggests that loss of
Gpm6a expression is a key genetic determinant of claus-
trophobia, but also sufficient to turn an unrelated stressor into
a trigger of a unique behavioral response. We note that
Gpm6a itself is widely expressed in the CNS, including
hippocampus and amygdala as known sites of fear condition-
ing. Thus, there are no reasons to believe that the encoded
membrane protein has evolved in the context of specific
behavioral functions. It is much more likely that membrane
protein Gpm6a, similar to other proteolipids,37,38 is a
cholesterol-associated tetraspan,39 that binds other neuronal
membrane proteins, which provide functional specificity. It is
thus intriguing that Gpm6a has been found to stimulate
endocytosis of m-opioid receptors from the surface of neuronal
cells.40,41 We note that opioids are well known to be involved
in regulation of fear/anxiety and their extinction in mouse
and man.24
Virtually nothing was known about the cause of claustro-
phobia. Typically, anectodal evidence suggested traumatic
experiences, such as in individuals that became trapped alive,
but these incidents cannot explain the high frequency
of claustrophobia in otherwise normal people. The cause or
trigger of some cases of claustrophobia may still be related
to exposure to narrow spaces,36 traumatic brain injury42 and
other traumatic experiences, such as surviving of mining
accidents, but these are mostly poorly documented.
Our report of a mutant mouse model for claustrophobia
suggests that also human claustrophobia can have a familial
predisposition. We could identify a genetic component of
claustrophobia, involving GPM6A expression and its post-
transcriptional regulation by the (stress-regulated) neuronal
miR124. These data suggest that GPM6A may contribute
to the normal stress response in mouse and human. Larger
studies in human samples would be required to assess
exactly to what extent variants of GPM6A act as a
claustrophobia-susceptibility gene.
At first glance, the two findings in mouse and human appear
contradictory, because the claustrophobic phenotype was
associated with the murine Gpm6a null mutation and the
human GPM6A c.*1834-C allele. The latter is predicted to
encode a more stable mRNA, due to the loss of its miR124-
binding site. However, both findings can be reconciled with the
compensation of Gpm6a (in the null mutant) by related
proteins, such as Gpm6b. These proteins substitute for
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Gpm6a in neurons and allow mutant animals to develop
and behave normally. However, when exposed to stress
the expression of these genes is not downregulated
(unlike Gpm6a), as evidenced by the gene expression
profiling that had identified and later confirmed Gpm6a as
the only stress-responsive proteolipid in the adult brain.1,30
Along these lines, we note that miR124, which acts as a
stress-regulated mediator of GPM6A downregulation, as
shown here, does not have comparable functional binding
sites in GPM6B. Thus, loss of dynamic proteolipid expression
in neurons (and the inability to downregulate these proteins)
may predispose to abnormal stress response, rather than the
loss of Gpm6a per se.
The detailed downstream mechanisms will have to be
explored in other conditional mouse mutants in the future.
Gpm6a drives the rate of endocytosis that downregulates the
steady-state level of m-opioid receptors at the surface of
neuronal cells.40,41 Thus, our data are compatible with a
hypothetical model, in which a stress-induced phobia/panic
disorder might be caused (in part) by a reduced feedback
regulation of endogenous opioid receptor signalling.
Obviously, interactions with other proteins that also influence
behavior may be functionally relevant, and we note that the
human serotonin transporter has been reported to interact in
cis with GPM6A and GPM6B43 (and Jana Haase, Dublin,
Ireland, personal communication), whereas another study has
implicated this serotonin transporter in human panic dis-
orders.44 In turn,GPM6Amay also be relevant as a modifier of
other diseases, and it is intriguing that an association has
been found betweenGPM6A and the severity of depression in
patients with schizophrenia.45 The ramification of GPM6A
downstream mechanisms are therefore likely complex and
beyond the scope of this study. However, by placing the
dynamic expression of GPM6A/Gpm6a both upstream and
downstream of stress perception in the brain, we suggest a
working model of GPM6A/Gpm6a as a neuronal ‘brake’ for
maintaining a healthy stress response.
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